Načítá se...
Review of Venetoclax in CLL, AML and Multiple Myeloma
Venetoclax is a highly selective and effective B-cell lymphoma-2 (BCL-2) inhibitor, which is able to reinstate the apoptotic potential of cancer cells. With its full repertoire yet to be explored, it has changed the therapeutic landscape in haematological malignancies, and most particularly chronic...
Uloženo v:
| Vydáno v: | J Pers Med |
|---|---|
| Hlavní autoři: | , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
MDPI
2021
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8225137/ https://ncbi.nlm.nih.gov/pubmed/34073976 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/jpm11060463 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|